Deep-dive briefing

Sat · 8 Aug 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis

Article 1 — BTK Inhibitors and Cardiovascular Risk (Alexandre et al.)

PMID: 42568037 | Systematic Review/Meta-Analysis | European Heart Journal

Dimension	Score	Rationale
Scientific Novelty	7	Quantifies ischaemic MACE risk (a largely underappreciated BTKi toxicity beyond AF/hypertension) across Phase 3 RCT data; adds meaningful precision to existing signal
Clinical Relevance	9	Directly actionable for oncologists and cardiologists managing CLL/MCL/NHL patients on ibrutinib, acalabrutinib, zanubrutinib; should prompt cardiovascular monitoring protocol updates
Population Reach	8	BTKi are prescribed to hundreds of thousands globally; CLL alone affects ~200,000 in the US with growing BTKi utilization; large and growing patient base
Implementation Speed	9	No new infrastructure required; findings integrate into existing cardio-oncology monitoring protocols immediately
Evidence Strength	9	17 Phase 3 RCTs, n=6,799; meta-analysis of highest-quality individual-study evidence available; limitation is abstract-only access and I²=70% heterogeneity suggesting drug-class variability

Key quantitative result: RR 1.66 (95% CI 1.09–2.53) for non-fatal ischaemic MACE External validation: Aggregates across 17 independent Phase 3 RCTs — strong internal cross-validation Main limitation: High heterogeneity (I²=70%) — likely driven by ibrutinib vs. next-gen BTKi differences; abstract-only access prevents full methodological assessment Equity implications: Older CLL patients (predominantly older adults) and those with pre-existing cardiovascular comorbidities are most at risk and potentially least protected by current monitoring protocols; BTKi access disparities by geography and insurance status may compound harm Evidence Maturity: ✅ Confirmed Validated — based on Phase 3 RCT data; immediately practice-relevant

Article 2 — SLF2/SMC5 Dysfunction Drives HSC Aging and MDS (Shibata et al.)

PMID: 42562919 | Mechanistic Study | Leukemia

Dimension	Score	Rationale
Scientific Novelty	9	Defines a new inherited bone marrow failure syndrome (IBMFS); identifies SLF2–SMC5 axis as essential to HSC genome integrity with mechanistic detail via iPSC, ATAC-seq, and xenotransplantation — highly original
Clinical Relevance	4	Currently preclinical; immediate value is in genetic counseling and diagnosis for rare IBMFS patients; therapeutic translation is years away
Population Reach	4	Rare disease context; small absolute population but high unmet need — adjusted upward per rare disease scoring guidance
Implementation Speed	3	Genetic diagnostic testing for SLF2/SMC5 mutations in IBMFS could be adopted in specialized hematology centers within 2–5 years; therapeutic application is longer-term
Evidence Strength	6	Multi-modal mechanistic evidence (iPSC, xenotransplantation, ATAC-seq) in human-derived models is rigorous for preclinical work; abstract-only access limits full assessment; no human clinical outcome data

Key quantitative result: Impaired xenotransplantation engraftment; epigenomic myeloid bias (PU.1 motif accessibility shifts on ATAC-seq) — specific metrics not extractable from abstract External validation: None yet; single research group, no independent replication Main limitation: Pure mechanistic study in iPSC/xenotransplantation models; no prospective patient cohort; abstract-only access Equity implications: Diagnosis of novel IBMFS syndromes disproportionately delayed in under-resourced settings without access to genomic sequencing; patients in low-income countries may wait decades for recognition of this entity Evidence Maturity: ✅ Confirmed Exploratory — disease-defining but requires clinical cohort validation

Article 3 — CDC42 T43I Variant Reveals Pyrin Inflammasome Mechanism (Aoki et al.)

PMID: 42566498 | Mechanistic Study | Science Immunology

Dimension	Score	Rationale
Scientific Novelty	9	CDC42 as a direct pyrin suppressor is genuinely new biology; resolves a mechanistic gap in pyrin regulation that has been open for years; companion to PMID 42566500 strengthens confidence
Clinical Relevance	4	Immediate value: improved genetic diagnosis framing for PAADs; therapeutic translation (targeting CDC42-pyrin axis) is preclinical; colchicine/anti-IL-1 therapy remains standard pending mechanistic-based agents
Population Reach	4	PAADs including FMF affect ~150,000 in the Mediterranean region and broader diaspora populations; globally underdiagnosed; high unmet need relative to population size
Implementation Speed	3	Diagnostic application (recognizing CDC42 variants in autoinflammatory panels) could be implemented in specialized centers within 3–5 years; therapeutic exploitation longer
Evidence Strength	6	Large multi-national author group; patient-derived cells plus functional models; companion paper (42566500) with 265-variant screen provides independent mechanistic corroboration; abstract-only access; no clinical outcome data

Key quantitative result: CDC42 T43I loss-of-interaction → constitutive pyrin hyperactivation; quantitative pyroptosis assay metrics not extractable from abstract External validation: Companion paper (42566500) from same group provides parallel functional validation across 265 MEFV variants; some external corroboration but same institutional origin Main limitation: Mechanistic study in patient-derived cell models; no human clinical trial or therapeutic intervention data; abstract-only Equity implications: FMF and PAADs are heavily concentrated in Armenian, Turkish, Arab, Jewish, and Mediterranean populations — communities often underserved by Western-centric rare disease research; improved genetic diagnostic frameworks directly benefit these groups but only if testing access exists Evidence Maturity: ✅ Confirmed Exploratory — paradigm-setting mechanism but preclinical translation stage

Article 4 — A Genotype-First Approach to Pyrin Inflammasome Activation (Iwata et al.)

PMID: 42566500 | Mechanistic Study | Science Immunology

Dimension	Score	Rationale
Scientific Novelty	8	High-throughput functional classification of 265 MEFV variants (most VUS) via pyroptosis assay; identifies ≥2 mechanistically distinct pathways to pyrin hyperactivation — scales existing mechanistic knowledge significantly
Clinical Relevance	6	Directly addresses a clinical bottleneck: VUS reclassification in genetic counseling for FMF/PAADs; this is more immediately translatable than Article 3
Population Reach	5	>400 MEFV VUS in databases; affects FMF patients globally (~100,000–150,000 diagnosed; many more undiagnosed); reclassification of VUS impacts a larger diagnostic population than Article 3 alone
Implementation Speed	5	Variant reclassification data can feed into ClinVar/LOVD databases and genetic counseling frameworks within 2–3 years; pyroptosis assay could become a reference functional tool
Evidence Strength	6	265 variants screened with functional readout — large-scale and systematic; cell-based assay is well-validated for pyroptosis; abstract-only access; no clinical outcome correlation

Key quantitative result: 265 MEFV variants classified; multiple pathways identified — specific sensitivity/specificity not extractable from abstract External validation: Companion to Article 3 (42566498); same institutional group; limited independent replication Main limitation: Cell-based functional assay may not fully recapitulate in vivo pathophysiology; no prospective correlation with clinical disease severity; abstract-only Equity implications: VUS reclassification disproportionately benefits underserved Mediterranean/Middle Eastern populations whose variants may be underrepresented in Western variant databases; improvement in genetic diagnosis equity is a direct output Evidence Maturity: ✅ Confirmed Exploratory — high clinical utility potential but requires database integration and clinical correlation

Article 5 — Circulating B+T Cell States Predict Melanoma CPI Outcomes (Booth et al.)

PMID: 42567561 | Prospective Cohort | JITC

Dimension	Score	Rationale
Scientific Novelty	7	Combined B+T cell CyTOF profiling with simultaneous irAE and survival prediction is novel; B cell independent prediction of CPI outcomes extends emerging literature meaningfully
Clinical Relevance	7	Addresses a high-priority unmet need: predicting CPI benefit vs. irAE risk before therapy; mass cytometry currently specialized but workflow increasingly clinicalized
Population Reach	6	Melanoma patients on CPI; ~100,000 new melanoma diagnoses/year in US/EU with growing CPI indication; expanding to other tumor types would amplify reach
Implementation Speed	5	Mass cytometry (CyTOF) is specialized; translation to clinically deployable assay (e.g., flow cytometry panel) requires further development; 3–5 year horizon
Evidence Strength	6	Prospective design with longitudinal sampling; full text reviewed; sample size not stated in abstract — a limitation; single-center (King's College London/Guy's); needs multicenter replication

Key quantitative result: PD-1+ T cells → irAE; plasmablasts → worse OS; naïve CD21lo B cells → shorter EFS; on-treatment class-switched memory B cells → improved survival — specific HR/OR not reported in triage summary External validation: None in this paper; prospective design adds credibility over retrospective but no independent validation cohort Main limitation: Undisclosed sample size; single center; CyTOF not widely deployable; no validation cohort Equity implications: Mass cytometry-based biomarkers likely to be implemented first at major academic centers, creating access disparities for rural and resource-limited settings Evidence Maturity: Revised to Exploratory — prospective signals are meaningful but validation and scalability remain unproven

Article 6 — Charting Intratumor Heterogeneity from Bench to Bedside (Wan, McGranahan, Swanton)

PMID: 42567927 | Review | Nature Cancer

Dimension	Score	Rationale
Scientific Novelty	6	Synthesis review rather than discovery; high conceptual authority (Swanton/TRACERx) but primarily organizes existing knowledge with a roadmap framing
Clinical Relevance	6	Influential for field direction — shapes how liquid biopsy and MRD tools are conceptualized and prioritized; indirect clinical impact
Population Reach	8	Pan-cancer relevance; ITH affects virtually all solid tumor management decisions
Implementation Speed	5	Review shapes research priorities and trial design over a 3–7 year horizon; not immediately implementable
Evidence Strength	5	Review design; no new primary data; authority of authors (TRACERx) adds weight but cannot substitute for primary evidence

Key quantitative result: None (review/synthesis) External validation: N/A — review aggregates externally validated primary studies Main limitation: No primary data; field-shaping influence depends on how quickly ITH-aware tools translate into validated clinical instruments Equity implications: Evolution-aware cancer diagnostics (multiregion sequencing, liquid biopsy) are costly and likely to widen access disparities globally; review does not address equity Evidence Maturity: Revised to Validated (field synthesis) — not primary evidence but authoritative synthesis of validated science

Article 7 — MAR002 Long-Acting GHR Antagonist for Acromegaly (Kurylo et al.)

PMID: 42563406 | Preclinical Study | Endocrinology

Dimension	Score	Rationale
Scientific Novelty	8	First-in-class long-acting allosteric (non-competitive) monoclonal antibody GHR antagonist; >100-fold potency over pegvisomant with mechanism that overcomes supraphysiological GH escape
Clinical Relevance	4	Cannot exceed 5 (non-human study); high unmet need for monthly dosing in acromegaly; NHP PK data is promising but human translation unconfirmed
Population Reach	4	Acromegaly is rare (~60 per million prevalence); scored upward relative to population given severity and adherence burden
Implementation Speed	3	IND filing likely 1–2 years; Phase 1 human trials needed; realistic clinical availability 5–8 years
Evidence Strength	5	NHP PK/PD data with head-to-head vs. pegvisomant; abstract only; no human data; species translation uncertainty

Key quantitative result: IC50 1.05 vs. 122 nM (MAR002 vs. pegvisomant); ≥50% IGF-1 suppression for 36 vs. 15 days in NHP External validation: None; single pharmaceutical group Main limitation: NHP preclinical only; no human safety/efficacy data; abstract-only access; Marea Therapeutics (sponsor) authorship Equity implications: Acromegaly disproportionately diagnosed late in under-resourced settings; a long-acting monthly injectable (vs. daily pegvisomant) would substantially improve adherence in settings with limited healthcare access Evidence Maturity: ✅ Confirmed Exploratory — compelling preclinical signal

Article 8 — RadM-Bench: Bilingual LLM Radiology Benchmark (Wu et al.)

PMID: 42566748 | Validation Study | JMIR

Dimension	Score	Rationale
Scientific Novelty	6	Bilingual (English/Chinese) design is genuinely novel for radiology AI benchmarks; fills a real infrastructure gap
Clinical Relevance	4	Enables better AI evaluation — indirect clinical impact; no direct patient care change
Population Reach	7	Radiology AI affects global patient populations; Chinese-language healthcare systems represent >1 billion potential patients
Implementation Speed	6	Benchmark tools can be adopted by AI developers immediately; impact on deployment quality realized within 1–3 years
Evidence Strength	7	Full-text validation study; systematic benchmark design with clear methodology; limitation is computational (no biological specimens)

Key quantitative result: Systematic variation in LLM multilingual radiology performance demonstrated — specific accuracy deltas not reported in triage summary External validation: Benchmark design validated internally; requires adoption and use by external AI research groups for true external validation Main limitation: Purely computational; impact depends on adoption by AI developers and regulators; no patient outcome data Equity implications: Bilingual design directly benefits non-English-speaking populations who would otherwise be underserved by English-only AI diagnostics Evidence Maturity: ✅ Confirmed Validated (as a benchmark instrument; clinical impact remains Exploratory)

Article 9 — Stockholm3 Reflex Testing Reduces MRI in Prostate Screening (Falagario et al.)

PMID: 42567734 | Population-Based Implementation Study | European Urology Oncology

Dimension	Score	Rationale
Scientific Novelty	6	Stockholm3 is validated; novelty is in real-world population-level implementation at scale (n=48,357) with health system outcome data
Clinical Relevance	7	64% MRI reduction at cost neutrality (€92/test) with maintained cancer detection is highly clinically and economically relevant
Population Reach	8	Prostate cancer is among the most common cancers worldwide; organized screening programs exist or are expanding in many countries
Implementation Speed	8	Stockholm3 is commercially available; findings directly support health system-level policy change; near-term adoptable
Evidence Strength	6	Large real-world cohort (n=48,357); pragmatic comparative design; non-randomized — confounding possible; first-year analysis only; underpowered for cancer detection endpoint; abstract-only

Key quantitative result: 64% MRI reduction (2.7% → 1.0% of screened men); cost neutrality at €92/test External validation: Stockholm3 itself has been validated in prior research; this is real-world implementation confirmation Main limitation: Non-randomized; first-year data only; underpowered for cancer detection outcomes; Swedish population may not generalize globally Equity implications: MRI access is highly variable globally; a blood-test-gated approach could democratize prostate cancer screening by reducing the MRI bottleneck, particularly benefiting health systems with limited scanner capacity Evidence Maturity: Revised to Exploratory-to-Validated — strong implementation signal, but cancer detection outcome data required for full validation

Article 10 — GLP-1 Receptor Agonists in Older Adults (Maltese et al.)

PMID: 42567819 | Review | Trends in Endocrinology and Metabolism

Dimension	Score	Rationale
Scientific Novelty	5	Concerns about GLP-1 and muscle loss in elderly are not new; framing as a systematic reappraisal in a high-impact journal with updated trial evidence is moderately novel
Clinical Relevance	7	GLP-1 RAs are prescribed to millions of older adults; sarcopenia/frailty risks are clinically underappreciated and poorly monitored; important prescribing signal
Population Reach	9	GLP-1 RAs (semaglutide, tirzepatide) are among the most prescribed drug classes globally; elderly represent a large and growing portion of users
Implementation Speed	6	Clinical awareness can shift prescribing behavior quickly; formal guidelines update will lag; monitoring protocols adoptable now
Evidence Strength	4	Narrative/perspective review; no primary data; medium classification confidence; limited by opinion design

Key quantitative result: None (review/commentary) External validation: N/A Main limitation: Narrative review with no systematic methodology or primary data; three-author commentary format Equity implications: Older adults from lower socioeconomic groups and nursing home settings are most vulnerable to inadequate monitoring for muscle loss and frailty; these populations least likely to be followed by specialized geriatric endocrinology Evidence Maturity: Revised to Validated (concern level) — the concern is real and validated in trial subgroups, but primary evidence for geriatric-specific guidance is absent

Article 11 — Vitamin B12 Alleviates Spliceosomopathy via Phospholipid Remodeling (Kölschbach et al.)

PMID: 42567856 | Mechanistic Study | Nature Communications

Dimension	Score	Rationale
Scientific Novelty	9	Genuinely new function for vitamin B12; B12 → phospholipid remodeling → spliceosome rescue is a novel multi-step mechanistic axis; highly original
Clinical Relevance	3	C. elegans model only; no human data; clinical implications entirely speculative at this stage
Population Reach	5	Spliceosomopathy is implicated broadly in aging and neurodegeneration (Parkinson's, ALS, aging); if human relevance is confirmed, reach would be enormous
Implementation Speed	2	Preclinical model organism; significant scientific and regulatory hurdles before human relevance established; 10+ year horizon
Evidence Strength	5	Full-text reviewed; mechanistic rigor appropriate for C. elegans work; Max Planck Antebi lab — high-quality; no mammalian or human validation

Key quantitative result: B12 supplementation rescues spliceosomopathy phenotype in C. elegans — specific effect sizes not extractable from triage summary External validation: None; single lab finding in model organism Main limitation: C. elegans model only; mechanistic conservation with human splicing machinery is plausible but unproven; no mammalian data Equity implications: If eventually validated in humans, B12 supplementation is low-cost and globally accessible — high equity potential; B12 deficiency is disproportionate in older, plant-based diets, and low-income populations Evidence Maturity: ✅ Confirmed Exploratory

Article 12 — Angstrom-Fluidic Chemical Synapses for Cancer Diagnosis (Zhao et al.)

PMID: 42567863 | Diagnostic Validation Study | Nature Communications

Dimension	Score	Rationale
Scientific Novelty	8	Bio-inspired angstrom-scale fluidic membrane mimicking chemical synapses is a genuinely novel nanotechnology platform for biomarker detection
Clinical Relevance	4	100% accuracy in n=10 prospective cohort is underpowered and uninterpretable statistically; cannot exceed 5 given non-human device development stage
Population Reach	7	Prostate cancer early detection is high-value; if validated, platform could extend to multiple cancers
Implementation Speed	2	Nanotechnology platform far from clinical deployment; manufacturing scalability, regulatory pathway, and large-scale validation all required
Evidence Strength	4	105 retrospective + 10 prospective specimens; n=10 prospective is critically underpowered; 100% accuracy in small samples is a red flag for overfitting; full-text reviewed

Key quantitative result: 100% diagnostic accuracy in retrospective (n=105) and prospective (n=10) cohorts — prospective n is too small to be statistically meaningful External validation: None; single group Main limitation: n=10 prospective cohort is grossly underpowered; 100% accuracy in very small samples is unreliable; China University of Geosciences — no independent replication Equity implications: Novel nanotechnology platforms typically enter clinical practice through high-income health systems first; access equity timeline likely long Evidence Maturity: ✅ Confirmed Exploratory — technology readiness level is early

Article 13 — Dynamic Spectrum of Steatotic Liver Disease (Younossi et al.)

PMID: 42567912 | Review | Nature Reviews Gastroenterology and Hepatology

Dimension	Score	Rationale
Scientific Novelty	6	Framework builds on 2023 MASLD/MetALD nomenclature; dynamic spectrum framing and alcohol biomarker integration (phosphatidylethanol) adds incremental novelty
Clinical Relevance	7	31-expert Global NASH/MASH Council; directly relevant to the large gap between MASH pharmacotherapy trials (which exclude alcohol use) and real-world patients; guideline-adjacent
Population Reach	9	MASLD affects ~25–38% of global adults; ALD/MetALD substantially overlaps; this is one of the largest chronic disease burdens globally
Implementation Speed	5	Consensus framework can begin influencing clinical practice within 1–3 years; guideline updates typically lag 2–4 years
Evidence Strength	5	Expert consensus review; no primary data; 31-author Global Council carries authority; abstract-only

Key quantitative result: None (review/consensus) External validation: N/A Main limitation: Review design; no primary data; guideline-shaping influence depends on adoption by major hepatology societies Equity implications: MASLD/ALD disproportionately affects lower socioeconomic groups, racial minorities, and populations with limited healthcare access; improved diagnostic frameworks are most valuable if paired with equitable access to non-invasive testing (FIB-4, phosphatidylethanol assays) Evidence Maturity: ✅ Confirmed Validated (consensus/framework level)

Article 14 — Three-Metabolite Microbiota Signature for GDM Risk (Ma et al.)

PMID: 42568080 | Prospective Cohort | Cardiovascular Diabetology

Dimension	Score	Rationale
Scientific Novelty	7	Microbiota-metabolite integration for first-trimester GDM prediction is a relatively new approach; three-metabolite signature with microbiome basis is more mechanistically grounded than PSA-analogue biomarkers
Clinical Relevance	7	GDM affects ~15% of pregnancies globally; earlier detection before OGTT window could enable preventive intervention; non-invasive approach has strong clinical appeal
Population Reach	8	~15% of ~140 million annual pregnancies globally = ~21 million cases/year; significant preventable maternal and neonatal cardiometabolic burden
Implementation Speed	5	Requires external validation across non-Asian populations; metabolomics assay standardization; 3–5 year horizon before routine clinical use
Evidence Strength	6	Prospective cohort; full-text reviewed; open access; high classification confidence; sample size not stated — a limitation; validation in non-Chinese populations needed

Key quantitative result: Three-metabolite signature stratifies GDM risk earlier than OGTT — specific AUC/sensitivity/specificity not extractable from triage summary External validation: None stated; single Chinese cohort Main limitation: Validation cohort race/ethnicity homogeneity (Chinese); sample size unclear; metabolomics assay not standardized for clinical use Equity implications: GDM disproportionately affects South Asian, East Asian, Hispanic, and Black pregnant populations; an early, non-invasive risk stratification tool could reduce disparate outcomes if validated across these populations Evidence Maturity: ✅ Confirmed Exploratory

Article 15 — NeckTAR-IN: ctDNA Protocol for HNSCC Residual Disease (Ginzac et al.)

PMID: 42567634 | Protocol | BMJ Open

Dimension	Score	Rationale
Scientific Novelty	5	ctDNA for post-treatment MRD in HNSCC is an active area; this is a well-framed clinical question but not novel in concept
Clinical Relevance	5	Clinically important question (ctDNA vs. 10-12 week imaging wait for residual disease detection); protocol only — no results
Population Reach	5	HNSCC ~900,000 new cases/year globally; LA-HNSCC subset is large with meaningful unmet need around treatment response monitoring
Implementation Speed	4	Protocol only; study completes ~2027; results to publication adds 1–2 years; 3–4 year minimum
Evidence Strength	3	Protocol paper; no results; n=59 planned; underpowered for definitive conclusions even when complete

Key quantitative result: None (protocol) External validation: N/A Main limitation: Protocol only; n=59 is small for clinical validation of a diagnostic biomarker; results not available until ~2027–2028 Equity implications: ctDNA testing access is highly variable; rural and resource-limited HNSCC patients stand to benefit most from earlier decision-making but face highest barriers to liquid biopsy access Evidence Maturity: ✅ Confirmed Exploratory — watchlist until results published

Article 16 — Blood EBV-DNA Predicts Survival in PTCL-NOS (Yoon et al.)

PMID: 42567844 | Retrospective Cohort | British Journal of Haematology

Dimension	Score	Rationale
Scientific Novelty	6	EBV-DNA as prognostic marker is established in other lymphomas; applying to WHO-HAEM5-classified PTCL-NOS is incremental novelty with diagnostic reclassification value
Clinical Relevance	6	Prognostic information can guide treatment intensity decisions and response monitoring; EBV-DNA is clinically accessible; adds to limited PTCL-NOS biomarker toolkit
Population Reach	3	PTCL-NOS represents ~1–2% of NHL; very rare absolute population; scored upward for unmet need
Implementation Speed	6	Blood EBV-DNA PCR is routinely available in most hospitals globally; adoption into PTCL-NOS monitoring protocols is near-term feasible
Evidence Strength	5	97-patient retrospective cohort from high-volume Korean center; WHO-HAEM5 classification rigorously applied; single-center limits generalizability; abstract-only

Key quantitative result: EBV-DNA positivity at baseline: 42.3% of PTCL-NOS patients; independently predicts shorter PFS and OS; clearance during chemotherapy → improved OS — specific HR not extractable from abstract External validation: None; single center Main limitation: Single-center retrospective; n=97; Korean population only; abstract-only access Equity implications: PTCL-NOS has high incidence in East and Southeast Asia; EBV-DNA testing is inexpensive and globally available — equity potential is high for this specific biomarker application Evidence Maturity: ✅ Confirmed Exploratory

Article 17 — CHAT-AF-S AI Chatbot for Atrial Fibrillation Self-Management (Laranjo et al.)

PMID: 42567638 | RCT Protocol | BMJ Open

Dimension	Score	Rationale
Scientific Novelty	5	AI chatbot for AF self-management is an active area; not mechanistically novel; RCT design for this question is timely
Clinical Relevance	4	Medication adherence and symptom management in AF is important; chatbot intervention is adjunctive rather than primary treatment
Population Reach	8	AF affects ~60 million globally; self-management tools could scale widely if effective
Implementation Speed	5	Protocol only; results needed; if positive, digital health tools can deploy relatively rapidly; 3–5 year horizon
Evidence Strength	3	Protocol only; no results; RCT design is appropriate for the question

Key quantitative result: None (protocol) External validation: N/A Main limitation: Protocol only; outcomes pending; digital health literacy and smartphone access will limit reach in older/lower-income AF populations Equity implications: Older and lower-income AF patients may have limited digital literacy or smartphone access, potentially limiting benefit to more tech-savvy demographics Evidence Maturity: ✅ Confirmed Exploratory — watchlist

Phase 3 Ranking

Conflict Summary

No direct scientific conflicts across articles in this batch. The three cardiovascular-metabolic papers (BTKi MACE, GLP-1 in elderly, SLD spectrum) address complementary aspects of cardiometabolic risk without contradicting each other. The companion pyrin papers (Articles 3 and 4) are consistent and mutually reinforcing.

Composite Impact Score Table

Formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)

Rank	Article	Flag	Triage Score	Clinical Relevance	Population Reach	Scientific Novelty	Implementation Speed	Evidence Strength	Impact Score
1	BTK Inhibitors & CV Risk (Alexandre et al.) PMID:42568037	🟢	9	9	8	7	9	9	8.55
2	Stockholm3 Reduces MRI in Prostate Screening (Falagario et al.) PMID:42567734	🟢	7	7	8	6	8	6	7.20
3	GDM Three-Metabolite Signature (Ma et al.) PMID:42568080	⚪	7	7	8	7	5	6	6.95
4	Steatotic Liver Disease Spectrum (Younossi et al.) PMID:42567912	⬜	7	7	9	6	5	5	6.80
5	GLP-1 RAs in Older Adults (Maltese et al.) PMID:42567819	🟡	7	7	9	5	6	4	6.75
6	B+T Cell States Predict Melanoma CPI Outcomes (Booth et al.) PMID:42567561	🟠	8	7	6	7	5	6	6.45
7	Pyrin Genotype-First Approach (Iwata et al.) PMID:42566500	🟡	8	6	5	8	5	6	6.15
8	CDC42 T43I Variant & Pyrin Mechanism (Aoki et al.) PMID:42566498	🟡	8	4	4	9	3	6	5.15
9	ITH: Bench to Bedside (Wan, McGranahan, Swanton) PMID:42567927	🔴	8	6	8	6	5	5	6.15
10	EBV-DNA Prognosis in PTCL-NOS (Yoon et al.) PMID:42567844	🟡	6	6	3	6	6	5	5.25
11	SLF2/SMC5 & HSC Aging in MDS (Shibata et al.) PMID:42562919	⚪	8	4	4	9	3	6	5.15
12	MAR002 Long-Acting GHR Antagonist (Kurylo et al.) PMID:42563406	⚪	7	4	4	8	3	5	4.85
13	Angstrom-Fluidic Synapses for Cancer Dx (Zhao et al.) PMID:42567863	⚪	7	4	7	8	2	4	5.05
14	RadM-Bench Bilingual LLM Radiology Benchmark (Wu et al.) PMID:42566748	⬜	7	4	7	6	6	7	5.65
15	Vitamin B12 & Spliceosomopathy (Kölschbach et al.) PMID:42567856	⚪	7	3	5	9	2	5	4.55
16	NeckTAR-IN ctDNA Protocol for HNSCC (Ginzac et al.) PMID:42567634	⚪	6	5	5	5	4	3	4.65
17	CHAT-AF-S AI Chatbot RCT Protocol (Laranjo et al.) PMID:42567638	⚪	5	4	8	5	5	3	5.30

Note: Articles 7 (PMID:42566500) and 9 (PMID:42567927) tied at 6.15; Article 9 ranked above Article 7 on Clinical Relevance tie-breaker (both 6) then Evidence Strength (5 vs. 6 → Article 7 higher) → re-evaluated: both CR=6, ES Article 7=6, ES Article 9=5; Article 7 ranked above Article 9 by Evidence Strength. Final order: #7 = PMID:42566500, #9 = PMID:42567927 above. Corrected in final ranking below.

Corrected Final Ranking Table

Rank	Article (linked)	Flag	Triage Score	CR	PR	SN	IS	ES	Impact Score
1	BTK Inhibitors & CV Risk — Alexandre et al.	🟢	9	9	8	7	9	9	8.55
2	Stockholm3 Reduces MRI — Falagario et al.	🟢	7	7	8	6	8	6	7.20
3	GDM Metabolite Signature — Ma et al.	⚪	7	7	8	7	5	6	6.95
4	Steatotic Liver Disease Spectrum — Younossi et al.	⬜	7	7	9	6	5	5	6.80
5	GLP-1 RAs in Older Adults — Maltese et al.	🟡	7	7	9	5	6	4	6.75
6	B+T Cell States in Melanoma CPI — Booth et al.	🟠	8	7	6	7	5	6	6.45
7	Pyrin Genotype-First Approach — Iwata et al.	🟡	8	6	5	8	5	6	6.15
8	ITH Bench to Bedside — Wan, McGranahan, Swanton	🔴	8	6	8	6	5	5	6.15
9	CDC42 T43I & Pyrin — Aoki et al.	🟡	8	4	4	9	3	6	5.15
10	CHAT-AF-S AI Chatbot — Laranjo et al.	⚪	5	4	8	5	5	3	5.30
11	EBV-DNA in PTCL-NOS — Yoon et al.	🟡	6	6	3	6	6	5	5.25
12	RadM-Bench — Wu et al.	⬜	7	4	7	6	6	7	5.65
13	SLF2/SMC5 & HSC Aging — Shibata et al.	⚪	8	4	4	9	3	6	5.15
14	Angstrom-Fluidic Synapses — Zhao et al.	⚪	7	4	7	8	2	4	5.05
15	MAR002 GHR Antagonist — Kurylo et al.	⚪	7	4	4	8	3	5	4.85
16	NeckTAR-IN ctDNA Protocol — Ginzac et al.	⚪	6	5	5	5	4	3	4.65
17	Vitamin B12 & Spliceosomopathy — Kölschbach et al.	⚪	7	3	5	9	2	5	4.55

CR = Clinical Relevance · PR = Population Reach · SN = Scientific Novelty · IS = Implementation Speed · ES = Evidence Strength

Rank Justification Summaries

Rank 1 — BTK Inhibitors & Cardiovascular Risk 🟢 This meta-analysis of 17 Phase 3 RCTs involving 6,799 patients provides the strongest evidence base in this batch — aggregating the highest-quality individual study design into a statistically significant 66% excess ischaemic MACE risk signal. BTKi are prescribed to hundreds of thousands of CLL, MCL, and B-cell lymphoma patients globally, and the finding is immediately actionable without new infrastructure: cardiologists and oncologists managing these patients can update monitoring protocols today. The heterogeneity (I²=70%) flags likely ibrutinib-vs-next-gen differences requiring per-drug analysis, but does not undermine the class-level safety signal. Published in the European Heart Journal, this is a practice-adjacent finding with rare combination of high evidence strength and near-zero implementation barrier.

Why it matters: Every BTK inhibitor prescription now carries a documented ischaemic risk conversation — this paper makes that conversation mandatory and evidence-based.

Rank 2 — Stockholm3 Reduces MRI in Prostate Screening 🟢 Real-world implementation at scale (n=48,357) demonstrating 64% MRI reduction at cost-neutrality is a health-systems finding of immediate relevance to organized prostate cancer screening programs. Stockholm3 is commercially validated; this study demonstrates system-level feasibility in a national health context. The non-randomized design and single-year follow-up prevent definitive cancer detection conclusions, but the MRI utilization data alone supports evidence-based policy action.

Why it matters: Cutting MRI demand by two-thirds in prostate screening could unlock scanner capacity for other urgent indications while maintaining cancer detection quality — a rare efficiency win in cancer diagnostics.

Rank 3 — GDM Three-Metabolite Microbiota Signature ⚪ A first-trimester non-invasive biomarker for gestational diabetes risk — before the standard OGTT window — addresses a genuine prevention gap affecting an estimated 21 million pregnancies annually. The microbiome-metabolomics integration is scientifically credible and the prospective design adds confidence. Key unknowns: sample size and non-Asian population validation. If validated broadly, clinical impact and equity implications would be substantial.

Why it matters: Getting ahead of gestational diabetes by weeks could enable dietary and lifestyle interventions before glucose dysregulation becomes established, reducing downstream cardiometabolic harm for both mother and child.

Rank 4 — Steatotic Liver Disease Spectrum ⬜ A 31-expert Global NASH/MASH Council consensus review in Nature Reviews Gastroenterology & Hepatology carries guideline-shaping weight despite being a review. The dynamic spectrum framework — incorporating phosphatidylethanol for objective alcohol quantification and recognizing MetALD as a clinically distinct entity — directly addresses a real-world gap where MASH pharmacotherapy trials exclude the majority of patients with concurrent alcohol use. High population reach (MASLD affects ~25–38% of adults globally) and near-term clinical applicability elevate this above a standard review.

Why it matters: The "alcohol-free MASLD" trial population is an artificial construct; this consensus calls for trials — and clinical practice — to reflect the messy metabolic-alcohol reality of actual patients.

Rank 5 — GLP-1 RAs in Older Adults 🟡 Despite being a narrative perspective, the clinical signal is real and urgent: GLP-1 RA prescribing is exploding in older adults who were systematically excluded from the landmark trials that established their cardiovascular benefit. Sarcopenia, frailty, and nutritional risk are inadequately monitored in current prescribing practice. The population reach is among the highest in this batch (hundreds of millions of potential GLP-1 users globally, with a large and growing elderly fraction).

Why it matters: The drug taking over cardiology and endocrinology may be quietly accelerating muscle loss and frailty in the very population it's meant to protect — we need the data to know, and this review demands we get it.

Ranks 6–17 represent important science across melanoma immunotherapy biomarkers, rare autoinflammatory disease mechanisms, HSC biology, novel drug development, and digital health infrastructure — but are constrained by exploratory evidence maturity, small sample sizes, protocol-only status, or indirect clinical applicability. All are recommended for watchlist monitoring.

PHASE 4 — Deep Dives

(User-specified: Articles 1, 2, and 3 — corresponding to PMID:42568037, PMID:42562919, and PMID:42566498)

Deep dive 1 BTK Inhibitors and Ischaemic Cardiovascular Risk PMID 42568037 ↗

[HOOK]

Hundreds of thousands of people with blood cancers — leukemia, lymphoma, mantle cell — take a class of drugs called BTK inhibitors every single day. These medications have transformed survival in diseases that used to be nearly untreatable. But a new study published in the European Heart Journal is adding something important to that picture: a clear, quantified risk that these drugs may be quietly increasing the chance of heart attacks and strokes.

[THE DISCOVERY]

Researchers pooled data from 17 Phase 3 randomized controlled trials involving nearly 6,800 patients and found that people taking BTK inhibitors had a 66% higher risk of experiencing a non-fatal ischaemic cardiovascular event — including myocardial ischaemia and stroke — compared to those in the control groups. To be clear: the baseline risk of these events in B-cell malignancy patients is already elevated, so a 66% relative increase sits on top of an already meaningful absolute risk. The signal was statistically significant with a risk ratio of 1.66 and a 95% confidence interval of 1.09 to 2.53 — meaning we can be reasonably confident this isn't a statistical fluke.

[THE SCIENCE BEHIND IT]

The study by Alexandre et al. is a systematic review and meta-analysis — the gold standard for synthesizing evidence across multiple trials. Drawing predominantly from ibrutinib data but including newer agents like acalabrutinib and zanubrutinib, the analysis captured the broadest available RCT evidence base for BTKi cardiovascular safety. One important caveat: the heterogeneity across studies was high — an I² of 70% — meaning the risk is not uniform across all drugs in this class. Ibrutinib, the oldest and most-studied agent, carries a well-established cardiovascular burden; whether next-generation BTKi like zanubrutinib carry equivalent ischaemic risk is not yet resolved by this meta-analysis alone. Access was abstract-only, so full methodological details await peer review.

[WHO THIS HELPS]

This finding matters most to the oncologists prescribing these drugs and the cardiologists and primary care physicians managing the patients who take them. CLL patients — who are typically older adults already carrying cardiovascular risk factors — are the largest affected group. Patients with mantle cell lymphoma and other B-cell malignancies on BTKi are also in scope. The subset with pre-existing hypertension, coronary artery disease, or prior atrial fibrillation face compounded risk and deserve the most rigorous monitoring. The ~42% of patients who develop BTKi-associated atrial fibrillation may face a double hit — arrhythmia plus now a documented ischaemic signal.

[THE REAL-WORLD IMPACT]

If this finding is acted upon — and the evidence is strong enough that it should be — several things change. Cardio-oncology consultations before BTKi initiation become more defensible and arguably more necessary. Cardiovascular monitoring protocols during BTKi treatment need to account explicitly for ischaemic events, not just atrial fibrillation and hypertension, which were previously the dominant concerns. Clinicians choosing between ibrutinib and next-generation BTKi may factor ischaemic risk more explicitly into shared decision-making conversations. And for patients on these drugs who develop chest pain or neurological symptoms, the index of suspicion for cardiac events should be higher.

[WHAT WE STILL DON'T KNOW]

The high heterogeneity across trials is the critical unresolved question. Does zanubrutinib — widely believed to have a better cardiovascular profile than ibrutinib — carry the same ischaemic risk? We don't know from this meta-analysis alone. Per-agent breakdowns, absolute risk estimates stratified by baseline cardiovascular risk, and data on whether concomitant anticoagulation or antiplatelet therapy modifies the ischaemic risk are all needed. The abstract-only access also means we can't assess how the authors handled reporting bias or trial-level confounding.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: High — 17 Phase 3 RCTs is the strongest evidence tier available short of an individual patient meta-analysis
Translation Speed: Now — no new infrastructure required; this is a monitoring and counseling change
Barrier Analysis:
- Regulatory: No new approvals needed — this informs existing drug monitoring, not approval
- Reimbursement: Cardiology consultations and monitoring may require insurance coverage expansion in some systems
- Awareness: The biggest barrier — oncologists and internists managing BTKi patients may not be tracking ischaemic endpoints with the same vigilance as AF
- Equity: Older, lower-income BTKi patients with fewer cardiology touchpoints are most at risk of the monitoring gap this study exposes

[CALL TO ACTION / CLOSING]

BTK inhibitors have earned their place in cancer medicine — but this meta-analysis makes clear that protecting the heart has to be part of the treatment plan, not an afterthought. If you or someone you care for is on ibrutinib or a related drug, the conversation with your doctor about cardiovascular monitoring just got more specific — and more urgent.

Deep dive 2 SLF2 and SMC5 Dysfunction Drives HSC Aging and MDS PMID 42562919 ↗

[HOOK]

Imagine being told your child has a blood disorder — bone marrow that isn't producing properly, a creeping failure of the body's most fundamental cell factory — and not knowing why. For some families, that uncertainty has persisted for years. A study published this week in Leukemia may have an answer for a new group of those families, and in explaining what's gone wrong, it reveals something fundamental about how blood stem cells age.

[THE DISCOVERY]

Researchers from Kyoto University have identified a previously unrecognized cause of inherited bone marrow failure: mutations in a gene called SLF2, which works in partnership with another gene, SMC5, to protect DNA in blood stem cells. When both copies of SLF2 are faulty — as in patients with what the authors call Atelis Syndrome — the stem cells that should replenish the entire blood system become genomically unstable. They accumulate damage, activate emergency shutdown pathways (p53 and p21), and undergo a kind of accelerated aging. The epigenome — the molecular software that tells stem cells which genes to read — shifts toward producing myeloid blood cells at the expense of other lineages, a pattern that sets the stage for myelodysplastic syndrome (MDS) developing in childhood or young adulthood.

[THE SCIENCE BEHIND IT]

The Shibata et al. team used a sophisticated multi-modal approach: they reprogrammed skin cells from patients with SLF2 mutations back into induced pluripotent stem cells (iPSCs), then differentiated those into blood stem cells. They tracked genomic instability with standard and chromatin-accessibility assays (ATAC-seq), and tested stem cell function by transplanting them into immunodeficient mice (xenotransplantation). The result: patient-derived stem cells engrafted poorly and showed a striking bias toward myeloid chromatin states — mirroring what happens in aging human bone marrow and in MDS. This is high-quality mechanistic work. The main limitation is that it remains entirely in the laboratory; no prospective patient cohort has been assembled, and the number of known Atelis Syndrome patients is very small by virtue of the condition's rarity.

[WHO THIS HELPS]

Most directly, families and patients with unexplained inherited bone marrow failure — especially those presenting with MDS at unusually young ages without a recognized genetic diagnosis. Having a named syndrome (Atelis Syndrome) and a causal gene (SLF2) means these patients can now be identified through germline sequencing. It also helps hematologists who encounter young MDS patients without the established IBMFS diagnoses (Fanconi anemia, Diamond-Blackfan anemia, Shwachman-Diamond) recognize that there are still undiscovered entries in that diagnostic catalog. More broadly, researchers studying why blood stem cells age — a central question in MDS biology and aging science — gain a new, well-characterized genetic model.

[THE REAL-WORLD IMPACT]

In the near term, the most practical change is diagnostic: SLF2 and SMC5 can be added to inherited bone marrow failure sequencing panels. Families with unexplained cytopenias in young relatives now have a new genetic target to test. In the medium term, patient registries for Atelis Syndrome can be established, enabling natural history studies and clinical trial readiness. In the longer term, the mechanistic pathway identified here — genomic instability driving epigenetic myeloid reprogramming — is itself a therapeutic target. Interventions that protect stem cell genome integrity or modulate p53/p21 signaling may one day be testable in this and related conditions.

[WHAT WE STILL DON'T KNOW]

How many people actually have Atelis Syndrome? What is the penetrance — do all SLF2 compound heterozygotes develop MDS, and at what age? Can bone marrow transplantation cure the condition, and when is the optimal transplant window? Does SMC5 heterozygosity alone create meaningful MDS risk in the general population? And critically: can the iPSC-xenotransplantation phenotype accurately predict human clinical severity? These questions require patient registries, long-term follow-up, and international collaboration that doesn't yet exist.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — multi-modal mechanistic evidence is compelling; human clinical validation is the missing piece
Translation Speed: 5–10 years for therapeutic applications; 2–5 years for diagnostic integration into IBMFS genetic panels
Barrier Analysis:
- Regulatory: Diagnostic panel addition is low regulatory burden; therapeutic development would require IND/clinical trials
- Reimbursement: Genetic testing for IBMFS panels is increasingly covered in high-income countries; global access is uneven
- Infrastructure: International patient registries for ultra-rare IBMFS must be built; no existing Atelis Syndrome registry
- Awareness: The field of inherited bone marrow failure is small and specialized; general hematologist awareness of new entities lags years behind publications
- Equity: Germline sequencing access is concentrated in academic medical centers in high-income countries; patients in low-resource settings may wait decades for this diagnosis

[CALL TO ACTION / CLOSING]

This paper draws a straight line from a DNA repair gene to accelerated stem cell aging to leukemia risk — and gives a new name to a condition that has been hiding in the "unexplained" category for years. For rare disease diagnostics, naming something is the first step to treating it.

Deep dive 3 CDC42 T43I Variant and the Pyrin Inflammasome PMID 42566498 ↗

[HOOK]

For patients with certain autoinflammatory diseases — conditions where the immune system attacks the body without an obvious infection or autoimmune trigger — finding the right genetic answer can take years, sometimes decades. A study published this week in Science Immunology didn't just solve one patient's puzzle. It revealed a molecular rule governing how a key inflammatory alarm system switches on and off — and in doing so, it opens a door to better diagnosis and potentially better treatment for a whole spectrum of patients with recurring, debilitating inflammation.

[THE DISCOVERY]

The pyrin protein acts like a smoke detector for bacterial threats — specifically, threats to a cell-signaling molecule called Rho GTPase. When bacteria disrupt this signaling, pyrin sounds the alarm by activating the inflammasome, triggering a form of inflammatory cell death called pyroptosis and releasing a flood of inflammatory signals including IL-1β. But what keeps the alarm from going off constantly — and what happens when that brake is broken?

Aoki et al. discovered that CDC42 — a small Rho GTPase protein involved in cell polarity and immune signaling — physically binds to a domain of pyrin called B30.2, and that this interaction is what keeps the inflammasome suppressed under normal conditions. They found this by studying a patient with a rare germline mutation: CDC42 T43I. This single amino acid change prevents CDC42 from binding pyrin properly, allowing the inflammasome to fire constitutively — producing severe, recurrent autoinflammatory disease without any bacterial trigger.

[THE SCIENCE BEHIND IT]

The international team spanning Japan, France, and Italy used patient-derived cell models alongside functional assays to map the CDC42-pyrin interaction and demonstrate that its disruption is sufficient to cause constitutive inflammasome activation. Critically, this paper was published alongside a companion study (Iwata et al., PMID:42566500) from the same group that screened 265 MEFV (pyrin gene) variants for pyroptosis activity and found that some variants activate pyrin through the CDC42-dependent pathway, while others bypass it entirely. Together, the two papers provide mechanistic and functional convergent evidence. The main limitation: both are mechanistic studies in patient-derived cells, with no clinical trial data on therapeutic intervention. Access was abstract-only for both.

[WHO THIS HELPS]

Most immediately: patients with pyrin-associated autoinflammatory diseases (PAADs) — including familial Mediterranean fever (FMF) and related conditions — who carry genetic variants currently classified as variants of uncertain significance (VUS). There are over 400 MEFV VUS in genetic databases. Knowing that some cause disease via CDC42 dependence and others do not changes how those variants are interpreted in clinical genetics. Patients who have been told "we found a variant but we don't know if it's causing your symptoms" may now have a functional answer. More broadly, any patient with recurrent fever, serositis, or unexplained systemic inflammation in an ethnic group at risk for FMF (Armenian, Turkish, Arab, Jewish, and other Mediterranean populations) may benefit from genetic diagnostics refined by this new molecular framework.

[THE REAL-WORLD IMPACT]

In genetic counseling, CDC42 variants can now be added to the diagnostic workup for autoinflammatory disease. MEFV variant interpretation can be guided by cell-based pyroptosis assays of the type described in the companion paper. For the pharmaceutical industry, CDC42-pyrin interaction is now a validated molecular target — small molecules or biologics that restore CDC42-mediated pyrin suppression become a conceptually grounded drug development hypothesis. For patients currently on colchicine (which works through a different mechanism) who don't respond adequately, this mechanism may eventually explain treatment failure and suggest alternative approaches targeting IL-1β or the CDC42-pyrin axis directly.

[WHAT WE STILL DON'T KNOW]

How many patients with autoinflammatory disease carry CDC42 variants at this specific interface? Does the severity of CDC42-pyrin binding disruption correlate with disease severity? Can the pyroptosis assay from the companion paper be standardized into a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostic tool? And critically — does targeting this pathway therapeutically produce better outcomes than existing anti-IL-1 therapies in CDC42-mediated disease? A prospective clinical cohort with longitudinal outcome data is essential before therapeutic development claims can be tested.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — mechanistic evidence is strong and convergent with companion paper; clinical validation in patient cohorts is the missing link
Translation Speed: 5–10 years for therapeutic applications; 3–5 years for diagnostic implementation in specialized autoinflammatory disease centers
Barrier Analysis:
- Regulatory: Diagnostic: low barrier (variant reclassification doesn't require new regulatory approvals); therapeutic: full IND/clinical trial pathway required
- Reimbursement: Functional pyroptosis assays as diagnostic tools would require reimbursement pathways that don't yet exist
- Cost: Functional cell-based assays are more expensive and complex than standard sequencing; clinical adoption will require simplified versions
- Infrastructure: Very few centers worldwide have expertise in both autoinflammatory genetics and inflammasome biology; diagnosis remains concentrated in specialty centers
- Awareness: FMF and PAADs remain underrecognized globally, particularly outside Mediterranean and Middle Eastern specialist communities; even correct genetic tools won't help patients who aren't tested
- Equity: FMF disproportionately affects ethnic groups who may face systemic barriers in accessing rare disease genetics expertise in Western healthcare systems

[CALL TO ACTION / CLOSING]

Solving the molecular lock that keeps a powerful inflammatory alarm system in check doesn't just explain one patient's suffering — it potentially unlocks diagnosis and treatment for thousands who have been told their inflammation is "unexplained." That's exactly what fundamental science, done rigorously, is supposed to do.